Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Business Update

Morepen Laboratories Business Update

Morepen Laboratories submitted its first Abbreviated New Drug Application (ANDA) to the U.S. FDA for Sitagliptin Tablets USP, marking a significant milestone in its integrated CDMO capabilities.

Source

BSE filing, NSE: MOREPENLAB. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Morepen Laboratories Ltd: key numbers

Share price
₹125.58
Market cap
₹6,881 Cr
Revenue (annual)
₹1,806 Cr
Net profit (annual)
₹94.88 Cr
P/E (TTM)
36.5×Sector 46.1×
Promoter holding
35.65%+0.00% QoQ
FII holding
3.43%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Morepen Laboratories Ltd

All →
13:32 IST NSE
Financial Results

Morepen Laboratories Q2 FY27 Results: Net Profit ₹88.9 Cr, Up 117.4% YoY

Morepen Laboratories Ltd reported revenue from operations of ₹746.5 Cr (+81.4% YoY) and net profit of ₹88.9 Cr (+117.4% YoY) for Q2 FY27.

Key figure
Net profit ₹88.9 Cr · +117.4% YoY

Other business update announcements

All →